Cutanix

Cutanix is a biopharmaceutical company dedicated to the development of innovative topical therapies for inflammatory dermatological conditions. The company's core technology is based on Quadrinone, a proprietary small molecule that acts as a selective inhibitor of the inflammatory response. This technology was specifically designed to treat skin disorders like rosacea, atopic dermatitis, and psoriasis without the adverse effects typically seen with topical steroids. Cutanix successfully launched the Dermalex line of products, which utilized Quadrinone to reduce skin redness and irritation. In 2012, the company was acquired by Suneva Medical, which integrated Cutanix's anti-inflammatory technology into its aesthetic and dermatological portfolio.